Arterial Capital Management, a life science-focused private equity firm, has appointed Dr Markus Weissbach as clinical trials director and a member of its board.
Dr Weissback brings over 25 years of life science industry experience to the post – with particular expertise in cardiology, infectious diseases and oncology – and is currently chief operating officer at DS Biopharma in Dublin.
He recently served as chief medical officer at Novartis Vaccines and Diagnostics, and chief executive officer of Averion International.
Prior to this Weissbach was a director at Takeda Europe, with responsibility for its clinical research and development unit. He also brings expertise from Knoll, CytoTools Biotech, Vasopharm, Cardiorentis, BernaBiotech and Sunesis.
David Evans, director of Arterial, said: “The ability to convert strong science and supporting data into strong investor returns is what makes an outstanding private equity business.
“The addition of Markus to our team is fantastic news for investors and investees alike.”